BioNTech to Lay Off 1,860 Employees in Post-COVID Restructuring

German biotechnology company BioNTech has announced a strategic transformation process following the COVID-19 pandemic, including the layoff of 1,860 employees. The decision is linked to the closure of production facilities, particularly in Germany and Singapore. BioNTech stated that the move is driven by declining demand for its COVID-19 vaccine and resulting overcapacity. The company aims to streamline its production infrastructure and use resources more efficiently as part of its long-term growth strategy. As part of the restructuring, BioNTech plans to shift its focus toward cancer drugs, leveraging the experience and revenue from its COVID-19 vaccine to advance R&D in oncology and develop new treatments. This strategic pivot is intended to enhance the company's future growth potential. The decision is seen as an example of post-pandemic transformation in the global biotechnology sector. BioNTech aims to strengthen its leadership in cancer immunotherapy by improving operational efficiency and reducing costs. The layoffs are expected to help the company achieve these goals. This is not investment advice.